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In a report submitted to the Ministry of Social Affairs
and Health, The National Agency for Medicines (NAM)
suggested that a new, national drug information centre,
based at NAM, should established in Finland. The cen-
tre would function independently and apart from NAM,
but making use of its services. As a separate centre, it
would be under the economic control of the Ministry of
Social Affairs and Health. The centre is envisaged to be
initially manned by eight experts, and to have an annual
budget of about 8 million Finnish marks (1,3 M EUR)
in 2002. It would be fully financed by appropriations
from the national state budget.
In the background to the above-mentioned report
was the often in the 1990s felt need for qualitative
improvements of drug therapy in accordance with
knowledge derived from research. This plan was recent-
ly been developed further under the project known as
ROHTO. The objective is to collect, summarise and dis-
seminate to health care professionals – especially physi-
cians – any information promoting rational and cost-
efficient drug therapy. The purpose would be to modify
prescribing practices along the lines of the knowledge
made available to the profession.
The primary function of the planned centre would be
to evaluate new medicines on the market, with the
emphasis on their therapeutic status and significance for
the economy as a whole. The information disseminated
by the centre should help the physician to decide where
to fit in the new medicines in his ”arsenal” of useful
and preferable medicines, thus balancing the effect of
commercially available information. This activity is
intended to exert influence and to modify physicians’
prescribing practices.
Making use of broad networks of experts, and col-
laborating with research institutes and scientists would
be the main types of activity of the national drug infor-
mation centre. In addition to using traditional media,
electronic publishing methods could be made use of in
disseminating information. Regional co-operation net-
works should also be established, and existing contacts
could, naturally, be used.
Practical evidence both in Finland and abroad sug-
gests that the information on research findings dissemi-
nated by the pharmaceutical industry itself can be selec-
tive, failing to give a full picture of the benefits and dis-
advantages of a medicine.  It is essential for the func-
tioning of the planned centre that it should be able to
use and publish the data on clinical studies and other
information submitted to NAM by the pharmaceutical
industry in the course of the marketing authorisation
procedure. Information on pharmacovigilance databases
and drug reimbursement statistics, as maintained by the
competent authorities, would be additional sources of
relevant background information for the centre. Gaining
access to the above-mentioned ”tools” calls, of course,
for political goodwill in the form of legislative reforms.
Denmark, for instance, is an encouraging example of
such a development, as a similar centre is already func-
tioning there.
The question which will now be asked is, could
NAM’s function as a collector and provider information
on medicines simply be extended, and could it be
financed with the revenue of fees from  industry or from
the national state budget? The credibility and the trans-
parency of the use of fees from the industry are mainly
at issue here. It would be difficult to authorise a phar-
maceutical product and consequently adopt a  very criti-
cal attitude vis-à-vis the said medicine. In addition, it
should be born in mind that the fees payable to NAM
by the pharmaceutical industry are intended to cover
only the costs arising from the processing of specific
marketing authorisations.
If there were genuine interest in establishing a
national drug information centre independent of com-
mercial interests, now would be a good time to take
action. The will to do that, which seemed to have a
broad base while the proposal was drawn up, is now
needed. Funds are also needed, but the necessary sum
would fall below 2 per mill of the sum total paid annu-
ally in drug reimbursements. 
Hannes Wahlroos
DIRECTOR GENERAL
National Agency for Medicines 
From words to deeds to get the message across –
more reliable drug information is needed
Editorial
Summary 
Translation Liisa Fellman-Paul
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Two thirds of patients suffering
from chronic pain exhibit  symp-
toms of depression.  A quarter of
them will also fulfil the diagnostic
criteria for it.  Combination treat-
ment with tramadol and an antide-
pressant is common in these pa-
tients.
Tramadol
The analgesic efficacy of tramadol 
in chronic pain is based on a weak
opioid effect and mechanisms that
increase the availability of serotonin
(5-HT) and noradrenaline (NA) in
the synapse.  Tramadol inhibits
serotonin and noradrenaline re-up-
take  at the presynaptic nerve end-
ings, and stimulates the release of 
5-HT from them.  General adverse
effects caused by tramadol include
nausea, vertigo, tiredness and
headache.  Adverse effects can pre-
vent effective long-term treatment,
especially in elderly patients.
Antidepressants
All antidepressants on the market
affect the re-uptake or metabolism
of serotonin or noradrenaline, or of
both.  Furthermore, the older tri-
cyclic antidepressants also have sev-
eral receptor effects (muscarinic and
histaminic) which may decrease pa-
tient compliance because of adverse
effects.  In the treatment  of chronic
pain such systems may also have
analgesic effects.
Selective serotonin re-uptake in-
hibitors (SSRI) act by inhibiting the
serotonin transporter which trans-
fers serotonin back to the cell at the
presynaptic nerve ending. SSRI-type
drugs on the market include fluoxe-
tine, fluvoxamine, paroxetine, ser-
traline and citalopram.  In small
doses (≤ 75 mg/day), venlafaxine is
mainly a serotonin re-uptake in-
hibitor, but in larger doses it also in-
hibits the re-uptake of noradrena-
line.  Nefazodone is both a 5-HT re-
uptake inhibitor and a 5-HT2 recep-
tor antagonist.  Reboxetine is a se-
lective noradrenaline re-uptake in-
hibitor but its direct effects on the 5-
HT system are very minor.  Mi-
anserin and mirtazapine also in-
crease 5-HT and NA transmission.
Pharmacodynamic interactions
In  theory, it is possible that the ef-
fects of both serotonin and noradre-
naline increase and reach a harmful
level when tramadol and antidepres-
sants are used concurrently.  Ad-
verse effects of serotonin have been
described when tramadol has been
used together with fluoxetine, par-
oxetine or sertraline (Table 1).  In
these cases the prevention of the
CYP2D6-mediated metabolism of
tramadol partly explains the possi-
ble  interaction  (see Pharmacokinet-
ic interactions ).
Even though case reports on the
co-administration of moclobemide
and tramadol have not been pub-
lished, with the exception of one
where a patient died due to a sero-
tonin syndrome after an overdose of
moclobemide, clomipramine and
tramadol, this combination should
be  regarded with extreme  caution.
It certainly causes increased  sero-
tonin release,  and the cell uptake
and metabolism are inhibited.  Sero-
tonin may be responsible for severe
adverse effects in some patients even
at normal dose levels.
The combination of amitriptyline
and other tricyclic antidepressants
with  tramadol may potentiate each
other’s serotonergic and noradrener-
gic effects.  The doses of amitripty-
line used for treating pain are very
small (10–50 mg/day), and problems
of interaction  with tramadol are
probably rather rare.
As with SSRI drugs, tramadol
can also lower the seizure threshold,
and this may be accentuated  when
they are administered together.  A
recent case report refers to a patient
who was treated at hospital with
tramadol, venlafaxin, prometazin
and paracetamol; the morning after
discharge from hospital the patient
started having  seizures as a result of
which patient died.  All tricyclic an-
tidepressants including mianserin
and maprotiline lower the seizure
threshold.
Lithium, which is specifically
used for a bipolar affective disorder,
also has serotonergic effects, and
consequently may also increase the
adverse effects of serotonin when
used concurrently with tramadol.
The effect of polymorphism of
CYP2D6
Tramadol is metabolised via
CYP2D6 to the M1 metabolite.  
5–10% of the population are slow
metabolisers due to polymorphism
of this enzyme, 1–10% are ultra
rapid, and the rest are rapid metab-
olisers.  The concentrations of  the
substrate are on average higher in
slow metabolisers than in the so-
called rapid metabolisers.  The dif-
ference is not, however, very signifi-
cant, and this  is evidently due to al-
ternative metabolic pathways. But
the concentrations of (+)-M1 meta-
bolite, which has an opioid effect
Interactions  of tramadol  with antidepressants
Summary 
Kari Raaska
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200 times higher than that of the
substrate, can vary by a factor of ten
between slow and fast metabolisers.
The analgesic effect of tramadol in
opioid responsive pain may be low
in slow metabolisers.
Pharmacokinetic  interactions
Many antidepressants such as fluox-
etine, paroxetine and venlafaxine
are substrates  for CYP2D6.  Con-
centrations of these drugs may be
considerably higher in slow metab-
olisers compared with fast metab-
olisers, which will increase the sero-
tonergic effects, and as regards ven-
lafaxine and tricyclic antidepressants
also the noradrenergic effects.  The
elimination of fluvoxamine may also
be significantly reduced in slow
CYP2D6 metabolisers. Even though,
unlike in fast metabolisers, the
CYP2D6 inhibitor does not increase
the tramadol concentrations in slow
metabolisers, the monoamine effects
of both tramadol and the above-
mentioned antidepressants are po-
tentiated owing to  higher concen-
trations of both drugs.
In the case reports outlined in
Table 1, the interaction of tramadol
especially with paroxetine and flu-
oxetine may relate  to the pharma-
cokinetic interactions.  Fluoxetine
and especially paroxetine inhibit the
tramadol-metabolising CYP2D6 en-
zyme and, consequently, the concen-
tration and serotonergic effects of
tramadol are increased.
Small doses of tricyclic antide-
pressants,  particularly amitriptyline,
are widely used in patients with neu-
ropathic pain.  A depressed patient
with pain can be prescribed a small
dose of amitriptyline for pains and
an SSRI drug for depression concur-
rently, especially if  he/she suffers
Table 1. Summary of case reports from the literature of the patients with suspected serotonin syndrome
Report/patient Other drugs Dose & dura- Dose & dura- Symptoms/ Therapy & result
tion of SSRI tion of tramadol duration
Mason & Blackburn, metaproterenol sertralin, dose? 300mg/day Atypical chest- Situation was dissolved
1997, female 42 yrs 10mg x4 po., > one year 3 weeks pain, sinustachy- in 24–36 h, when 
asthma, backache pravastatin 20mg, cardia 140/min, tramadol was
severe depression triamcinolone inh. x 4 confusion, withdrawn and  
chloroxazone 250mg x 4 psychos, sertralin dose halved 
omeprazole 20mg, agitation, to 50 mg/day
paracetamol 325mg sweating,
1–2 x 4-6, terfenadine tremor,
60mg x 2 duration:
3 weeks,
fluctuating
Kesavan & Sobaia ? fluoxetin 400mg/day tremor, head- procyclidin, 
1999, female 31 yrs 40mg/day ca 2 weeks ache, agitation, clonazepam and
fibromyalgia, 3 yrs anxiety, blefaro- diazepam started,
endometriosis spasm, fever, fluoxetin and  trama-
sweating, speech dol were withdrawn
problems, symptoms relieved 
high S-prolactin, in 7 days, 
duration: 10 days, total recovery
fluctuating in 2 months
Lantz & al . , 1998, multivitamins paroxetine     150 mg/day,  nausea, paroxetine and 
female 78 yrs, 20 mg/day, 3 days sweating, tramadol were 
severe depression, duration? irritability, withdrawn,  
osteoporosis, myasthenia, recovery
fractures of confusion, in 4-5 days 
dorsal fever, 
vertebrae, tachycardia
macular duration: 3 days
degeneration 
Lantz & al . , 1998 valproate 250mgx2, paroxetine 10 200 mg/day,  nausea, cyproheptadine
female 88 yrs, quinapril 5mg x1, mg/day, 2 days sweating, 2 mgx3, paroxetine 
bipolar affective timolol eye drops, 2 years vomiting, and tramadol were
syndrome, ASA 50mg x4 sleeplessness, withdrawn, 
hypertension, vertigo recovery
coronary artery duration: 2 days in 4-5 days
disease, 
glaucoma
Egberts & al . ,  1997 no other drugs paroxetine 20 100 mg/day shaking, tramadol was with-
male 47 yrs, mg/day, (one tablet) sweating, drawn, paroxetine 
depression, 4 months muscular tics, dose halved, patient 
arthralgia loss of conscious- regained 
ness duration: consciousness 
12 hours in 12 hours, recovery 
in 1 week 
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from adverse effects with  the larger
doses of amitriptyline which are re-
quired for the treatment of depres-
sion.  Tricyclic antidepressants are
prone to CYP2D6-mediated interac-
tions, and the concentrations may
increase significantly when adminis-
tered together with a CYP2D6 in-
hibitor (e.g. paroxetine).  Conse-
quently, their serotonergic and nor-
adrenergic effects will also be poten-
tiated.  From the pharmacokinetic
point of view, sertraline and citalo-
pram are probably the safest antide-
pressants among the SSRI drugs for
use with tricyclic agents.
Patients also often have other
diseases and drugs which may in-
crease the adverse effects of tra-
madol and antidepressants (Table
2).
Adverse effects of serotonin
In the majority of patients who ex-
perience adverse effects at the start
of treatment the effects will, when
the treatment is continued, cease or
decrease significantly within 1–2
weeks.  Nevertheless, some patients
will have significant adverse effects
already at small doses.  Common
adverse effects of serotonin-selective
drugs include nausea,  loss of ap-
petite,  muscular tics, sleep distur-
bances,  anxiety and problems of
sexual performance.  When the ad-
verse effects are severe the condition
is, with certain reservations, called
serotonin syndrome.  Sternbach re-
quires that at least three of the fol-
lowing symptoms should be present
at the same time: change in the state
of psyche/consciousness, agitation,
myoclonus, hyperreflexia, sweating,
tremor, diarrhoea, coordination dis-
turbance and fever.  The clinical pic-
ture can have a close  resemblance
to malignant neuroleptic syndrome,
and it can be fatal.  In practice, the
risk of  serotonin syndrome is al-
most non-existent if SSRI drugs are
used in  therapeutic doses.  The con-
dition may develop as a result of a
significant overdose, or if another
agent with a serotonergic effect is
used at the same time.
The symptoms of serotonin syn-
drome may disappear quickly with-
out any actual treatment on with-
drawal of the serotonergic drug.  Se-
vere cases may even require inten-
sive care treatment.
Conclusion
When tramadol and antidepressants
are prescribed for the same patient,
the possibility of their interaction
should be considered.  Relatively
few reports have been published on
severe interactions in combined
treatment with antidepressants and
tramadol.  They should nevertheless
be taken seriously since they are
conceivable on the basis of the phar-
macokinetic properties and pharma-
codynamic effects of these therapeu-
tic substances.  When we take into
consideration the possible problems
caused by interactions of tramadol
and antidepressants, patients will no
longer be exposed to unnecessary
adverse effects.  It is recommended
that the prescription of tramadol be
avoided in patients on moclobemide
therapy.  Sertraline and citalopram
of the SSRI group of drugs are prob-
ably the safest to use concurrently
with tramadol, due to the  signifi-
cantly lower CYP2D6 enzyme inihi-
tion they show  compared with oth-
er drugs.  The pharmacodynamic
potential of an interaction  is never-
theless the same with all SSRI prepa-
rations, and therefore, none of them
can be considered risk-free.
Table 2. Cases of death reported to NAM where the patients have used tramadol concurrently with antidepressants.
Patient Medication Symptoms Concentration Other drug concentrations 
of tramadol. 
Therapeutic level  
0.1–0.3 mg/l
Female 83 yrs, tramadol 200mg/day, found dead, 4.4 mg/l doxepin: 0.7 mg/l 
fell, surgery due doxepine 100mg/day cause of death: (therapeutic level 0.03–0.15 mg/l)
to hip fracture, enalapril, furosemid, tramadol intoxication 
was recovering amoxicillin, doxicillin, 
from surgery methotrexate 5mg/day, 
ketoprofen, insulin
Male 79 yrs tramadol, perphenazine, found dead 1.4 mg/l amitriptyline 0.1 mg/l 
levomepromazine, at home (therapeutic level < 0.2 mg/l
paracetamol+codeine, 
amitriptyline (dosage?)
Male 72 yrs tramadol, moclobemide, died during hip 0.8 mg/l dextropropoxyphene 0.4 mg/l, 
dextropropoxyphene operation, moclobemide 2 mg/l
(dosage?) cause of death: 
fat embolism 
Male 22 yrs tramadol (dosage?),               after one week 
sertraline 50 mg/day of use, loss  
of consciousness and 
convulsions
of 1 min duration  
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Summary 
The National Agency for Medicines
received 713 reports of suspected
adverse drug reactions (ADR) dur-
ing the year 2000. A total of 377
(53%) of them were serious. The to-
tal number of reports was slightly
smaller than the year before but the
proportion of serious reactions has
increased somewhat. The reports are
distributed fairly evenly among vari-
ous drugs; 10 or more reports were
received for only 12 substances. The
table is not a list of the most harm-
ful drugs and it cannot be used for a
comparison of safety between the
various substances. Reports on all
ADRs are invited especially on new
drugs, and this results in a greater
number of reports on those than on
many old familiar drugs. The list al-
so contains such old drugs which of-
ten cause serious ADRs, or the asso-
ciated safety aspects of which have
often been discussed.
The list is headed by a second
generation antipsychotic, clozapine,
of which the majority of reports
(65%) concern granulocytopenia or
agranulocytosis. This reaction is
well-known; changes in white blood
cell count occur in about 1% of pa-
tients on clozapine therapy. Due to
the frequency and severity of these
adverse effects, a white blood cell
count and differential count must be
done before clozapine therapy is
started. Leukocyte counts should be
monitored weekly for the first 18
weeks of the therapy, and at least
once a month thereafter. The
amount of clozapine prescribed
should not exceed the amount re-
quired between two leukocyte
counts. The patient should be re-
minded to contact a physician im-
mediately if any symptoms of infec-
tion appear, such as fever or sore
throat.
The majority of ADR reports re-
ceived among antibacterials con-
cerned levofloxacin, which is a fluo-
roquinolone antibiotic. Fourteen of
the reports were on tendinitis or
rupture of the Achilles tendon. Ten-
dinitis caused by fluoroquinolones
was discussed in TABU for the first
time in 1996. Since then the ADR
register has received a total of 42 re-
ports on tendinopathies caused by
fluoroquinolones, over a third of
which were ruptures of the tendon.
The use of fluoroquinolones has in-
creased by about 75% since 1996.
Levofloxacin is responsible for the
major part of this increase. It has
been marketed in Finland since mid
1998.
From year to year quite a large
number of ADR reports have been
received on nitrofurantoin, which is
used in urinary tract infections. Dur-
ing 2000 a total of 21 reports were
submitted concerning this drug, two
thirds of them associated with lung
reactions, most commonly pulmon-
ary infiltrates or pulmonary fibrosis.
Three of the cases were fatal. These
patients were 71–92 years of age
and they had used nitrofurantoin as
prophylaxis against chronic urinary
tract infections. Due to the possibili-
ty of severe pulmonary reactions,
patients on nitrofurantoin therapy
should be under special monitoring
with respect to any pulmonary
symptoms such as cough and/or dys-
pnoea.
Among antifungal agents, the
majority of ADR reports were asso-
ciated with the use of oral terbin-
afine. Most of them were reports of
various itching skin reactions. Taste
disturbances associated with
terbinafine therapy have also been
reported.
The majority of ADRs among
nonsteroidal anti-inflammatory
drugs were associated with nime-
sulide. Over half of the reports were
associated with liver reactions, ei-
ther elevation of liver enzymes (5
cases) or hepatitis (8 cases). There
has been a big increase in the use of
nimesulide because it is claimed to
be a rather selective COX-2-in-
hibitor and to cause fewer gastroin-
testinal ulcers than older anti-in-
flammatory drugs. Owing to its liver
Register of adverse drug reactions in 2000
Marja-Leena Nurminen
SENIOR MEDICAL OFFICER
Leena Sommarberg
RESEARCHER
National Agency for Medicines
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The most frequently reported sub-
stances in the register of adverse reac-
tions 2000 received by the NAM
Drugs            Number of  reports
clozapine 31
levofloxacin 25
nimesulide 25
nitrofurantoin 21
terbinafine 15
iopromide 15
valproate 14
atorvastatin 13
sulfasalazine 10
fluvastatin 10
rofecoxib 10
vigabatrin 10
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reactions, the product information
on nimesulide was updated last year.
The SPC (summary of product char-
acteristics) contains a warning, for
instance, that patients with abnor-
mal liver function test values and/or
symptoms indicating liver damage,
should be carefully monitored and
the medication should be with-
drawn. These patients should not be
re-exposed to nimesulide. A short
review on liver reactions associated
with nonsteroidal anti-inflammatory
drugs was recently published in
TABU.
In 2000, a total of 16 suspected
ADRs were reported to have been
associated with the new COX-2 se-
lective anti-inflammatory drugs,
coxibs, 10 of which were associated
with the use of rofecoxib and 6 with
celecoxib. Reports associated with
celecoxib therapy were most com-
monly of various allergic reactions
and skin rashes. The use of rofecox-
ib was associated with isolated re-
ports of oedema, haematuria, pruri-
tus, nausea and vomiting. Treatment
with rofecoxib was associated with
gastric ulcer in one patient; the pa-
tient was on concurrent low-dose
ASA therapy. Two cases of suspected
interaction were reported for rofe-
coxib administered concurrently
with warfarin: the anticoagulation
effect of warfarin had been potenti-
ated in one, and reduced in the oth-
er. It is known from previous experi-
ence that rofecoxib may prolong the
thromboplastin time (INR) in pa-
tients on warfarin. The response to
oral anticoagulants should therefore
be carefully monitored, especially at
the start of rofecoxib therapy or
when the dose is changed. Due to
possible interactions, the blood co-
agulation activity should also be
monitored carefully in patients re-
ceiving concurrent treatment with
celecoxib and warfarin. Rofecoxib
was introduced onto the Finnish
market at the end of 1999 and cele-
coxib half a year later.
Among cholesterol synthesis pre-
venting statins, the majority of ADR
reports received were associated
with the use of atorvastatin and flu-
vastatin. Typically reported ADRs of
both drugs included muscle pains,
elevated creatinine phosphokinase
and liver enzyme values.  There has
been a big increase in the consump-
tion of statins in Finland since the
mid 1990’s.  Both atorvastatin and
fluvastatin are among the three most
frequently used statins at present.
Iopromide is an iodine-contain-
ing contrast medium with low os-
molality which is used for angiogra-
phy, urography and computer to-
mography. A total of 15 ADR re-
ports were received in 2000 by
NAM. The majority of them in-
volved allergic reactions (urticaria,
anaphylaxis). The SPC recommends
that special care should be exercised
in patients with hypersensitivity to
iodine containing contrast media.
Patients with a history of allergy are
also inclined to suffer hypersensitivi-
ty reactions more readily than oth-
ers. Efforts to prevent these reac-
tions can be made by administering
e.g. antihistamines and/or corticos-
teroids to the patients before exami-
nation.
The majority of reports received
among antiepileptic agents con-
cerned valproate. In two cases the
number of epileptic seizures was re-
ported to have increased when val-
proate was administered concurrent-
ly with meropenem. Meropenem is
an antibiotic used for the treatment
of severe infections and it may de-
crease the serum concentration of
free valproate. Four ADR reports in-
volved fetal valproate syndrome in a
child where the mother had used
valproate during pregnancy. Val-
proate is considered somewhat to in-
crease the risk of foetal abnormali-
ties and cause neural tube defects.
Epilepsy as such will also increase
the frequency of abnormalities, and
untreated epilepsy may be associated
with seizures which present a risk
for both the mother and the foetus.
Since some antiepileptic drugs can
decrease the serum folic acid con-
centration or expose to neural tube
defects, attempts can be made to re-
duce the risk of these defects by ad-
ministering folic acid tablet during
the planning of a pregnancy and the
first trimester.
Ten ADR reports were submitted
last year about vigabatrin, all of
them dealing with visual distur-
bances. Vigabatrin is known to
cause permanent narrowing of the
visual field in at least a third of pa-
tients. Due to the defects in the visu-
al field use of the drug has been re-
stricted, and vigabatrin can nowa-
days be used in combination treat-
ment for epilepsy only in cases
where all alternative appropriate
drug combinations have proven in-
sufficient in efficacy or are poorly
tolerated. Vigabatrin is also used in
children as monotherapy for infan-
tile spasms. The visual field should
be mapped out before treatment,
and monitoring of the visual field
should be repeated at six-monthly
intervals during treatment. It is only
rarely possible to perform visual
field examinations on children under
the age of 9. The visual capacity of
all children should nevertheless be
assessed and children should be sent
for examination by an opthalmolo-
gist as necessary.
Ten ADRs were reported for sul-
fasalazine. The adverse effects were
typical for sulfasalazine: six cases of
hematological disorders, three cases
of liver reactions and one case of
skin rash.
Translation Mervi Moisander
